Drug Approvals

QFITLIA (fitusiran): A New Treatment for Hemophilia A and B Approved by the FDA on March 28, 2025

QFITLIA (fitusiran): A New Treatment for Hemophilia A and B Approved by the FDA on March 28, 2025

What is it prescribed for? QFITLIA is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children aged 12 years and older with hemophilia A or B, with or without factor VIII or IX inhibitors​. What is the name of the drug and what does it do? The brand name is QFITLIA (pronounced "kew-fit-lee-ah"), and the generic name...

Zelsuvmi: A New Topical Treatment for Molluscum Contagiosum Approved on January 5, 2024

Zelsuvmi: A New Topical Treatment for Molluscum Contagiosum Approved on January 5, 2024

What is it prescribed for? ZELSUVMI is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older What is the name of the drug and what does it do? Zelsuvmi (pronounced zel-SOOV-mee), (generic name: berdazimer), is a medication indicated for the topical treatment of molluscum contagiosum (MC) in adults...

Miplyffa: A New Treatment for Niemann-Pick Disease Type C Approved on September 20, 2024

Miplyffa: A New Treatment for Niemann-Pick Disease Type C Approved on September 20, 2024

What is the name of the drug and what does it do? Miplyffa (pronounced MYE-pli-fah), generic name arimoclomol, is a medication used to treat neurological symptoms of Niemann-Pick disease type C (NPC). NPC is a rare genetic disorder that affects the body’s ability to process cholesterol and other fats, leading to damage in the brain and other organs. Miplyffa is...

Anktiva: A New Treatment for Nonmuscle Invasive Bladder Cancer Approved on April 22, 2024

Anktiva: A New Treatment for Nonmuscle Invasive Bladder Cancer Approved on April 22, 2024

What is it prescribed for? ANKTIVA is indicated with Bacillus Calmette-GuĂ©rin (BCG) for the treatment of adult patients with BCGunresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.  What is the name of the drug and what does it do? Anktiva (pronounced ank-TEE-vah), (generic name: nogapendekin alfa...

Duvyzat: A New Treatment for Duchenne Muscular Dystrophy Approved on March 21, 2024

Duvyzat: A New Treatment for Duchenne Muscular Dystrophy Approved on March 21, 2024

What is it prescribed for? DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.  What is the name of the drug and what does it do? Duvyzat (pronounced doo-VY-zat), (generic name: givinostat), is a medication indicated for the treatment of Duchenne muscular dystrophy...